CareDx, Inc
NASDAQ:CDNAMedical - Diagnostics & Research
+$1.19 today
- Market cap
- $3.91B
- Beta
- 2.48
- P/E (TTM)
- -154.0
- EPS (TTM)
- -$0.16
Volume 0.54M
Average 0.74M
CDNA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
CareDx, IncNASDAQ: CDNA
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $74.35M rose 43.1% year over year, ahead of the +19.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 22.2% from the prior quarter. Over 3 fiscal years it compounded at +2.3% a year.
Context
- Selling, general & admin amounted to 55.3% of revenue in FY2025, down 6.2 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $316.03M (+50.3%) for the fiscal year ending Dec 2026, a step up from the +2.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $74.35M+22.2% QoQ
- Last fiscal yearDec 2025
- $210.21M+2.3% YoY
- LTMJun 2026
- $247.69M+19.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 210.21M USD
- Year-over-year change
- +2.3%
- 4-year CAGR
- +8.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 210.21M | +2.3% |
| FY2024 | 2024-12-31 | 205.5M | +2.1% |
| FY2023 | 2023-12-31 | 201.2M | +2.4% |
| FY2022 | 2022-12-31 | 196.42M | +29.0% |
| FY2021 | 2021-12-31 | 152.21M | — |
Selling, General & Admin vs competitors
How CDNA compares with its peers on the latest reported figures
- CDNA's LTM Jun 2026 selling, general & admin of $247.69M is the 5th highest of the 8 companies compared; the peer median is $292.26M.
- Its year-over-year change of +19.2% is the 5th highest of 8, against a peer median of +22.3%.
- Selling, general & admin amounts to 54.1% of revenue for CDNA, versus a peer median of 46.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.25B | +22.3% | +26.0% | 46.4% | |
| LTM Jun 2026 | $586.14M | +3.0% | -1.1% | 27.9% | |
| LTM Mar 2026 | $537.7M | -3.2% | +1.5% | 64.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $292.26M | +58.0% | -10.9% | 64.3% |
| LTM Jun 2026 | $247.69M | +19.2% | +2.3% | 54.1% | |
| LTM Jun 2026 | $201.58M | -7.5% | +6.6% | 35.9% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $180.71M | +60.0% | — | 45.5% |
| LTM Mar 2026 | $166.18M | +30.2% | +2.2% | 51.9% | |
| Peer median (excluding CDNA) | $292.26M | +22.3% | +1.8% | 46.4% | |
Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 296.4M | 321.79M | 280.32M | 333.79M | 379.81M |
| Cost of Revenue | 97.39M | 112.21M | 102M | 109.63M | 123.24M |
| Gross Profit | 199.01M | 209.58M | 178.33M | 224.16M | 256.57M |
| Gross Margin | 67.1% | 65.1% | 63.6% | 67.2% | 67.6% |
| Research & Development | 76.53M | 90.39M | 81.87M | 72.41M | 71.43M |
| Selling, General & Admin | 152.21M | 196.42M | 201.2M | 205.5M | 210.21M |
| Operating Expenses | 228.73M | 286.81M | 381.69M | 183.39M | 281.64M |
| Depreciation & Amortization | 11.89M | 16.01M | 19.82M | 19.76M | 20.42M |
| EBITDA | (20.2M) | (60.23M) | (84.92M) | (34M) | (4.66M) |
| EBITDA Margin | -6.8% | -18.7% | -30.3% | -10.2% | -1.2% |
| Operating Income | (29.73M) | (77.23M) | (203.36M) | 40.77M | (25.07M) |
| Operating Margin | -10.0% | -24.0% | -72.5% | 12.2% | -6.6% |
| Interest Income | 160K | 3.76M | 11.87M | 11.77M | 9.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.36M) | 997K | 13.22M | 12.09M | 3.99M |
| Income Before Tax | (32.09M) | (76.23M) | (190.14M) | 52.86M | (21.08M) |
| Pre-Tax Margin | -10.8% | -23.7% | -67.8% | 15.8% | -5.6% |
| Income Tax Expense | (1.43M) | 379K | 141K | 310K | 271K |
| Net Income | (30.66M) | (76.61M) | (190.28M) | 52.55M | (21.35M) |
| Net Margin | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% |
| EPS (Basic) | (0.59) | (1.44) | (3.54) | 1.00 | (0.40) |
| EPS (Diluted) | (0.59) | (1.44) | (3.54) | 0.93 | (0.40) |
| Weighted Avg Shares | 52.24M | 53.32M | 53.76M | 52.77M | 53.29M |
| Weighted Avg Shares (Diluted) | 52.24M | 53.32M | 53.76M | 56.62M | 53.29M |
CareDx, Inc
NASDAQ:CDNA
Intrinsic Alpha fair value
Locked
Current Price
$74.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.